Alunbrig (Brigatinib)

General Description:

Alunbrig (brigatinib) is an oral treatment for adults with advanced non-small cell lung cancer (NSCLC) that is ALK-positive. It targets the ALK protein, which plays a role in cancer cell growth and spread. The medication is usually taken once daily, beginning with a lower dose that may be increased based on how well it is tolerated.

GettingAlunbrig (brigatinib)in India

Alunbrig (brigatinib)has been approved in countries like the U.S. and Europe but is not yet available for commercial sale in India. However, it is accessible through the Named Patient Program (NPP) for eligible patients.

MitoGENE helps Indian patients accessAlunbrig (brigatinib)legally and safely under their doctor’s supervision. We handle the documentation, regulatory approvals, and logistics to ensure compliance with Indian regulations.

If you or your loved one may benefit from Alunbrig (brigatinib),MitoGENE is here to support your journey to access this treatment.

Disease Indications: Lung Cancer

Manufacturer: ARIAD Pharmaceuticals, Inc

Usage: Oral

Medicine Approved by:

• European Medical Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA)

Available Dosage Form& Package

• 30 Tablets of 30 mg
• 30 Tablets of 90 mg
• 30 Tablets of 180 mg

Shipping: Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.